1
|
Archer TC, Ehrenberger T, Mundt F, Gold MP, Krug K, Mah CK, Mahoney EL, Daniel CJ, LeNail A, Ramamoorthy D, Mertins P, Mani DR, Zhang H, Gillette MA, Clauser K, Noble M, Tang LC, Pierre-François J, Silterra J, Jensen J, Tamayo P, Korshunov A, Pfister SM, Kool M, Northcott PA, Sears RC, Lipton JO, Carr SA, Mesirov JP, Pomeroy SL, Fraenkel E. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 2018; 34:396-410.e8. [PMID: 30205044 PMCID: PMC6372116 DOI: 10.1016/j.ccell.2018.08.004] [Citation(s) in RCA: 118] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 06/28/2018] [Accepted: 08/03/2018] [Indexed: 12/18/2022]
Abstract
There is a pressing need to identify therapeutic targets in tumors with low mutation rates such as the malignant pediatric brain tumor medulloblastoma. To address this challenge, we quantitatively profiled global proteomes and phospho-proteomes of 45 medulloblastoma samples. Integrated analyses revealed that tumors with similar RNA expression vary extensively at the post-transcriptional and post-translational levels. We identified distinct pathways associated with two subsets of SHH tumors, and found post-translational modifications of MYC that are associated with poor outcomes in group 3 tumors. We found kinases associated with subtypes and showed that inhibiting PRKDC sensitizes MYC-driven cells to radiation. Our study shows that proteomics enables a more comprehensive, functional readout, providing a foundation for future therapeutic strategies.
Collapse
Affiliation(s)
- Tenley C Archer
- Department of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA; Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Tobias Ehrenberger
- Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA
| | - Filip Mundt
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| | - Maxwell P Gold
- Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA
| | - Karsten Krug
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Clarence K Mah
- Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA
| | - Elizabeth L Mahoney
- Department of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| | - Colin J Daniel
- Department of Molecular and Medical Genetics, Oregon Health and Science University (OHSU), Portland, OR, USA
| | - Alexander LeNail
- Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA
| | - Divya Ramamoorthy
- Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA
| | - Philipp Mertins
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - D R Mani
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Hailei Zhang
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Michael A Gillette
- Harvard Medical School, Boston, MA, USA; Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital (MGH), Boston, MA, USA
| | - Karl Clauser
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Michael Noble
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Lauren C Tang
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Jessica Pierre-François
- Department of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| | - Jacob Silterra
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - James Jensen
- Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA
| | - Pablo Tamayo
- Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA; Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA, USA
| | - Andrey Korshunov
- CCU Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neuropathology, Heidelberg University, Heidelberg, Germany
| | - Stefan M Pfister
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - Marcel Kool
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Paul A Northcott
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Rosalie C Sears
- Department of Molecular and Medical Genetics, Oregon Health and Science University (OHSU), Portland, OR, USA
| | - Jonathan O Lipton
- Department of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA
| | - Steven A Carr
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
| | - Jill P Mesirov
- Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA; Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA, USA.
| | - Scott L Pomeroy
- Department of Neurology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
| | - Ernest Fraenkel
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
| |
Collapse
|
2
|
Lieber DS, White E, Silterra J, Zhong S, Brennan T, Coyne M, Kennedy M, Gandara DR, Kowanetz M, Paul SM, Schleifman E, Li Y, Rittmeyer A, Fehrenbacher L, Amler L, Riehl T, Cummings C, Hegde PS, Zou W, Sandler A, Ballinger M, Mok T, Shames DS, Lipson D, Malboeuf C, Fabrizio D. Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC. Cancer Immunol Res 2018. [DOI: 10.1158/2326-6074.tumimm17-a41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The need to identify biomarkers that predict benefit to checkpoint inhibitor therapies has led to the discovery and development of tumor mutational burden (TMB), a measure of potential tumor neoantigenicity derived from tissue biopsies that has shown clinical utility across a range of tumor types. A significant fraction of patients, however, are not candidates for tissue biopsies, presenting the need for blood-based methods to determine TMB. Here we describe the development of an assay to identify TMB from cell-free DNA derived from blood (bTMB). We present the analytic validation and clinical feasibility data that support the application of bTMB in a prospective clinical trial, BFAST (NCT03178552), evaluating the anti-PD-L1 agent atezolizumab in patients with non-small cell lung cancer (NSCLC).
Methods: The bTMB assay surveys somatic base substitutions down to 0.5% allele frequency across 394 genes from as little as 1% tumor content in a cell free DNA (cfDNA) sample derived from blood. Analytic validation was focused on establishing accuracy and precision of the bTMB measurement, as well as the minimum amount of cell-free and circulating tumor DNA required to make precise and reliable bTMB calls. The accuracy of two bTMB cutoffs was established against TMB derived from FoundationOne, an analytically validated TMB platform. Precision was evaluated by comparing the reproducibility of bTMB calls across replicate samples. We also retrospectively analyzed plasma samples from the OAK (NCT02008227) and POPLAR (NCT01903993) trials with the bTMB assay to determine the association of bTMB with atezolizumab clinical activity. The biomarker evaluable population (BEP) included 211 patients in POPLAR (intention-to-treat [ITT] =287) and 583 patients in OAK (excludes patients with known EGFR/ALK mutations; ITT=850), with blood samples available for targeted genomic sequencing. Assay positivity was defined as the presence of a number of somatic base substitutions greater than or equal to the bTMB cutoffs.
Results: The average positive percent agreement (PPA), negative percent agreement (NPA) and positive predictive value (PPV) across the bTMB cutoffs were 95%, 100% and 100%, respectively. The average precision was 96%, with a coefficient of variation of 7%. The assay limit of detection was defined as 1% tumor content in at least 20 ng of cfDNA. In POPLAR, improved progression-free survival (PFS) and overall survival (OS) hazard ratios (HRs) with atezolizumab vs docetaxel were observed for patients with bTMB at or above a range of bTMB thresholds compared with the ITT and BEP populations. In OAK, PFS benefit with atezolizumab vs docetaxel was observed at bTMB thresholds ≥10 (cut point ≥10: HR 0.73; n=251) compared with BEP (HR 0.87, 95% CI 0.73-1.04; n=585). bTMB did not correlate with PD-L1 expression as measured by VENTANA SP142 immunohistochemistry.
Conclusions: We have developed and analytically validated a blood-based assay to determine TMB with high accuracy and precision, using as little as 1% tumor content in a sample with 20 ng of cfDNA. Retrospective analyses from POPLAR and OAK data provide the first demonstrations that blood-based measurement of TMB may be associated with atezolizumab clinical efficacy in second-line NSCLC. Thus, the bTMB assay may provide a non-invasive biomarker to identify patients who derive clinical benefit from single agent PD-1/PD-L1 inhibition. Prospective studies using bTMB are currently ongoing in patients with first-line NSCLC, including BFAST and B-F1RST (NCT02848651).
Citation Format: Daniel S. Lieber, Emily White, Jacob Silterra, Shan Zhong, Tina Brennan, Michael Coyne, Mark Kennedy, David R. Gandara, Marcin Kowanetz, Sarah M. Paul, Erica Schleifman, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Lukas Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Wei Zou, Alan Sandler, Marcus Ballinger, Tony Mok, David S. Shames, Doron Lipson, Christine Malboeuf, David Fabrizio. Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr A41.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Yan Li
- 3Genentech, South San Francisco, CA,
| | | | | | | | | | | | | | - Wei Zou
- 3Genentech, South San Francisco, CA,
| | | | | | - Tony Mok
- 6Chinese University of Hong Kong, Hong Kong, Hong Kong
| | | | | | | | | |
Collapse
|
3
|
Fabrizio D, Lieber D, Malboeuf C, Silterra J, White E, Coyne M, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, Cummings C, Peters E, Kowanetz M, Lipson D, Otto G. Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab. Immunology 2018. [DOI: 10.1158/1538-7445.am2018-5706] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Fabrizio D, Malboeuf C, Lieber D, Zhong S, He J, White E, Coyne M, Silterra J, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, Cummings C, Peters E, Kowanetz M, Lipson D, Otto G. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Silterra J, Gillette MA, Lanaspa M, Pellé KG, Valim C, Ahmad R, Acácio S, Almendinger KD, Tan Y, Madrid L, Alonso PL, Carr SA, Wiegand RC, Bassat Q, Mesirov JP, Milner DA, Wirth DF. Transcriptional Categorization of the Etiology of Pneumonia Syndrome in Pediatric Patients in Malaria-Endemic Areas. J Infect Dis 2017; 215:312-320. [PMID: 27837008 DOI: 10.1093/infdis/jiw531] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Accepted: 10/28/2016] [Indexed: 12/20/2022] Open
Abstract
Background Pediatric acute respiratory distress in tropical settings is very common. Bacterial pneumonia is a major contributor to morbidity and mortality rates and requires adequate diagnosis for correct treatment. A rapid test that could identify bacterial (vs other) infections would have great clinical utility. Methods and Results We performed RNA (RNA-seq) sequencing and analyzed the transcriptomes of 68 pediatric patients with well-characterized clinical phenotype to identify transcriptional features associated with each disease class. We refined the features to predictive models (support vector machine, elastic net) and validated those models in an independent test set of 37 patients (80%-85% accuracy). Conclusions We have identified sets of genes that are differentially expressed in pediatric patients with pneumonia syndrome attributable to different infections and requiring different therapeutic interventions. Findings of this study demonstrate that human transcription signatures in infected patients recapitulate the underlying biology and provide models for predicting a bacterial diagnosis to inform treatment.
Collapse
Affiliation(s)
| | - Michael A Gillette
- Broad Institute of MIT and Harvard, Cambridge.,Massachusetts General Hospital.,Harvard Medical School
| | - Miguel Lanaspa
- Barcelona Institute for Global Health, Barcelona Centre of International Health Research, Hospital Clínic-Universitat de Barcelona.,Centro de Investigação em Saúde de Manhiça
| | - Karell G Pellé
- Broad Institute of MIT and Harvard, Cambridge.,Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health
| | - Clarissa Valim
- Broad Institute of MIT and Harvard, Cambridge.,Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health
| | | | - Sozinho Acácio
- Centro de Investigação em Saúde de Manhiça.,National Institute of Health, Health Ministry, Maputo, Mozambique
| | | | - Yan Tan
- Broad Institute of MIT and Harvard, Cambridge.,Bioinformatics Program, Boston University
| | - Lola Madrid
- Barcelona Institute for Global Health, Barcelona Centre of International Health Research, Hospital Clínic-Universitat de Barcelona.,Centro de Investigação em Saúde de Manhiça
| | - Pedro L Alonso
- Barcelona Institute for Global Health, Barcelona Centre of International Health Research, Hospital Clínic-Universitat de Barcelona.,Centro de Investigação em Saúde de Manhiça
| | | | | | - Quique Bassat
- Barcelona Institute for Global Health, Barcelona Centre of International Health Research, Hospital Clínic-Universitat de Barcelona.,Institució Catalana de Recerca i Estudis Avançats, Passeig Lluís Companys 23, 08010 Barcelona.,Centro de Investigação em Saúde de Manhiça
| | - Jill P Mesirov
- Broad Institute of MIT and Harvard, Cambridge.,Department of Medicine, University of California, San Diego
| | - Danny A Milner
- Broad Institute of MIT and Harvard, Cambridge.,Harvard Medical School.,Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health.,Brigham and Women's Hospital, Boston, Massachusetts
| | - Dyann F Wirth
- Broad Institute of MIT and Harvard, Cambridge.,Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health
| |
Collapse
|
6
|
Valim C, Ahmad R, Lanaspa M, Tan Y, Acácio S, Gillette MA, Almendinger KD, Milner DA, Madrid L, Pellé K, Harezlak J, Silterra J, Alonso PL, Carr SA, Mesirov JP, Wirth DF, Wiegand RC, Bassat Q. Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia. Am J Respir Crit Care Med 2016; 193:448-59. [PMID: 26469764 DOI: 10.1164/rccm.201506-1100oc] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
RATIONALE Plasma-detectable biomarkers that rapidly and accurately diagnose bacterial infections in children with suspected pneumonia could reduce the morbidity of respiratory disease and decrease the unnecessary use of antibiotic therapy. OBJECTIVES Using 56 markers measured in a multiplexed immunoassay, we sought to identify proteins and protein combinations that could discriminate bacterial from viral or malarial diagnoses. METHODS We selected 80 patients with clinically diagnosed pneumonia (as defined by the World Health Organization) who also met criteria for bacterial, viral, or malarial infection based on clinical, radiographic, and laboratory results. Ten healthy community control subjects were enrolled to assess marker reliability. Patients were subdivided into two sets: one for identifying potential markers and another for validating them. MEASUREMENTS AND MAIN RESULTS Three proteins (haptoglobin, tumor necrosis factor receptor 2 or IL-10, and tissue inhibitor of metalloproteinases 1) were identified that, when combined through a classification tree signature, accurately classified patients into bacterial, malarial, and viral etiologies and misclassified only one patient with bacterial pneumonia from the validation set. The overall sensitivity and specificity of this signature for the bacterial diagnosis were 96 and 86%, respectively. Alternative combinations of markers with comparable accuracy were selected by support vector machine and regression models and included haptoglobin, IL-10, and creatine kinase-MB. CONCLUSIONS Combinations of plasma proteins accurately identified children with a respiratory syndrome who were likely to have bacterial infections and who would benefit from antibiotic therapy. When used in conjunction with malaria diagnostic tests, they may improve diagnostic specificity and simplify treatment decisions for clinicians.
Collapse
Affiliation(s)
- Clarissa Valim
- 1 Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.,2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Rushdy Ahmad
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Miguel Lanaspa
- 3 Barcelona Institute for Global Health, Barcelona Center of International Health Research, and Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.,4 Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | - Yan Tan
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.,5 Bioinformatics Program, Boston University, Boston, Massachusetts
| | - Sozinho Acácio
- 4 Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.,6 National Institute of Health, Health Ministry, Maputo, Mozambique
| | - Michael A Gillette
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.,7 Massachusetts General Hospital, Boston, Massachusetts.,8 Harvard Medical School, Boston, Massachusetts
| | - Katherine D Almendinger
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Danny A Milner
- 1 Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.,2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.,8 Harvard Medical School, Boston, Massachusetts.,9 Brigham and Women's Hospital, Boston, Massachusetts; and
| | - Lola Madrid
- 3 Barcelona Institute for Global Health, Barcelona Center of International Health Research, and Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.,4 Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | - Karell Pellé
- 1 Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.,2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Jaroslaw Harezlak
- 10 Richard M. Fairbanks School of Public Health and School of Medicine, Indiana University, Indianapolis, Indiana
| | - Jacob Silterra
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Pedro L Alonso
- 3 Barcelona Institute for Global Health, Barcelona Center of International Health Research, and Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.,4 Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | - Steven A Carr
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Jill P Mesirov
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.,5 Bioinformatics Program, Boston University, Boston, Massachusetts
| | - Dyann F Wirth
- 1 Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.,2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Roger C Wiegand
- 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
| | - Quique Bassat
- 3 Barcelona Institute for Global Health, Barcelona Center of International Health Research, and Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.,4 Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| |
Collapse
|
7
|
Herman JD, Rice DP, Ribacke U, Silterra J, Deik AA, Moss EL, Broadbent KM, Neafsey DE, Desai MM, Clish CB, Mazitschek R, Wirth DF. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. Genome Biol 2015; 15:511. [PMID: 25395010 DOI: 10.1186/preaccept-1067113631444973] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND Drug resistance remains a major public health challenge for malaria treatment and eradication. Individual loci associated with drug resistance to many antimalarials have been identified, but their epistasis with other resistance mechanisms has not yet been elucidated. RESULTS We previously described two mutations in the cytoplasmic prolyl-tRNA synthetase (cPRS) gene that confer resistance to halofuginone. We describe here the evolutionary trajectory of halofuginone resistance of two independent drug resistance selections in Plasmodium falciparum. Using this novel methodology, we discover an unexpected non-genetic drug resistance mechanism that P. falciparum utilizes before genetic modification of the cPRS. P. falciparum first upregulates its proline amino acid homeostasis in response to halofuginone pressure. We show that this non-genetic adaptation to halofuginone is not likely mediated by differential RNA expression and precedes mutation or amplification of the cPRS gene. By tracking the evolution of the two drug resistance selections with whole genome sequencing, we further demonstrate that the cPRS locus accounts for the majority of genetic adaptation to halofuginone in P. falciparum. We further validate that copy-number variations at the cPRS locus also contribute to halofuginone resistance. CONCLUSIONS We provide a three-step model for multi-locus evolution of halofuginone drug resistance in P. falciparum. Informed by genomic approaches, our results provide the first comprehensive view of the evolutionary trajectory malaria parasites take to achieve drug resistance. Our understanding of the multiple genetic and non-genetic mechanisms of drug resistance informs how we will design and pair future anti-malarials for clinical use.
Collapse
|
8
|
Herman JD, Rice DP, Ribacke U, Silterra J, Deik AA, Moss EL, Broadbent KM, Neafsey DE, Desai MM, Clish CB, Mazitschek R, Wirth DF. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. Genome Biol 2015. [PMID: 25395010 PMCID: PMC4272547 DOI: 10.1186/s13059-014-0511-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Drug resistance remains a major public health challenge for malaria treatment and eradication. Individual loci associated with drug resistance to many antimalarials have been identified, but their epistasis with other resistance mechanisms has not yet been elucidated. Results We previously described two mutations in the cytoplasmic prolyl-tRNA synthetase (cPRS) gene that confer resistance to halofuginone. We describe here the evolutionary trajectory of halofuginone resistance of two independent drug resistance selections in Plasmodium falciparum. Using this novel methodology, we discover an unexpected non-genetic drug resistance mechanism that P. falciparum utilizes before genetic modification of the cPRS. P. falciparum first upregulates its proline amino acid homeostasis in response to halofuginone pressure. We show that this non-genetic adaptation to halofuginone is not likely mediated by differential RNA expression and precedes mutation or amplification of the cPRS gene. By tracking the evolution of the two drug resistance selections with whole genome sequencing, we further demonstrate that the cPRS locus accounts for the majority of genetic adaptation to halofuginone in P. falciparum. We further validate that copy-number variations at the cPRS locus also contribute to halofuginone resistance. Conclusions We provide a three-step model for multi-locus evolution of halofuginone drug resistance in P. falciparum. Informed by genomic approaches, our results provide the first comprehensive view of the evolutionary trajectory malaria parasites take to achieve drug resistance. Our understanding of the multiple genetic and non-genetic mechanisms of drug resistance informs how we will design and pair future anti-malarials for clinical use. Electronic supplementary material The online version of this article (doi:10.1186/s13059-014-0511-2) contains supplementary material, which is available to authorized users.
Collapse
|
9
|
Katz Y, Wang ET, Silterra J, Schwartz S, Wong B, Thorvaldsdóttir H, Robinson JT, Mesirov JP, Airoldi EM, Burge CB. Quantitative visualization of alternative exon expression from RNA-seq data. Bioinformatics 2015; 31:2400-2. [PMID: 25617416 DOI: 10.1093/bioinformatics/btv034] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 01/15/2015] [Indexed: 11/12/2022] Open
Abstract
MOTIVATION Analysis of RNA sequencing (RNA-Seq) data revealed that the vast majority of human genes express multiple mRNA isoforms, produced by alternative pre-mRNA splicing and other mechanisms, and that most alternative isoforms vary in expression between human tissues. As RNA-Seq datasets grow in size, it remains challenging to visualize isoform expression across multiple samples. RESULTS To help address this problem, we present Sashimi plots, a quantitative visualization of aligned RNA-Seq reads that enables quantitative comparison of exon usage across samples or experimental conditions. Sashimi plots can be made using the Broad Integrated Genome Viewer or with a stand-alone command line program. AVAILABILITY AND IMPLEMENTATION Software code and documentation freely available here: http://miso.readthedocs.org/en/fastmiso/sashimi.html
Collapse
Affiliation(s)
- Yarden Katz
- Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, Department of Biology, MIT, Cambridge, MA
| | | | | | | | - Bang Wong
- The Broad Institute of Harvard, MIT, Cambridge, MA, USA
| | | | | | | | - Edoardo M Airoldi
- The Broad Institute of Harvard, MIT, Cambridge, MA, USA, Department of Statistics, Harvard University, Cambridge, MA, USA and
| | - Christopher B Burge
- Department of Biology, MIT, Cambridge, MA, Department of Biological Engineering, MIT, Cambridge, MA
| |
Collapse
|
10
|
Abstract
Soft X-rays (< 1Kev) are of medical interest both for imaging and microdosimetry applications. X-ray sources at this low energy present a technological challenge. Synchrotrons, while very powerful and flexible, are enormously expensive national research facilities. Conventional X-ray sources based on electron bombardment can be compact and inexpensive, but low x-ray production efficiencies at low electron energies restrict this approach to very low power applications. Laser-based sources tend to be expensive and unreliable. Energetiq Technology, Inc. (Woburn, MA, USA) markets a 92 eV, 10W(2pi sr) electrode-less Z-pinch source developed for advanced semiconductor lithography. A modified version of this commercial product has produced 400 mW at 430 eV (2pi sr), appropriate for water window soft X-ray microscopy. The US NIH has funded Energetiq to design and construct a demonstration microscope using this source, coupled to a condenser optic, as the illumination system. The design of the condenser optic matches the unique characteristics of the source to the illumination requirements of the microscope, which is otherwise a conventional design. A separate program is underway to develop a microbeam system, in conjunction with the RARAF facility at Columbia University, NY, USA. The objective is to develop a focused, sub-micron beam capable of delivering > 1 Gy/second to the nucleus of a living cell. While most facilities of this type are coupled to a large and expensive particle accelerator, the Z-pinch X-ray source enables a compact, stand-alone design suitable to a small laboratory. The major technical issues in this system involve development of suitable focusing X-ray optics. Current status of these programs will be reported.
Collapse
Affiliation(s)
- S F Horne
- Energetiq Technology, Inc; Woburn MA, 01801 USA
| | | | | |
Collapse
|